Welcome to Medicon Valley Alliance Good Morning Meeting with IQVIA on:
Value creation in a changing world:
Optimising clinical trial success through a purposeful use of data and technology
With over 4,000 assets in clinical development, developing medical innovation that can truly stand out has become increasingly more challenging for biotech players.
Designing a compelling patient-centric value proposition with concrete chances of clinical success, attracting the required funding and ultimately leading to downstream commercial impact is a complex art.
We see Patient Reported Outcomes (PRO) have been leveraged as an emerging path to support the approval process over the past few years. Between 2012 and 2016, approximately 22% of orphan drugs approved by the EMA incorporated PROs, and in oncology, 70% of indications for 49 EMA and FDA approved drugs included PRO data in their regulatory submissions.
In this session, the IQVIA team will showcase with real case studies how the early use of data and technology applied throughout the clinical development process can help optimise the return on investment of drug development.
This session is geared towards both emerging and established biopharma players as well as financial investors aiming to boost the value of their investments.
Date: Tuesday October 29th 2019
Time: 8:30 – 10:30
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Danmark – Ground floor
Program
|
8:30 – 9:00 |
Registration & Coffee |
|
9:00 – 9:05 |
Welcome |
|
9:05 – 10:00 |
Value creation in a changing world: Optimising clinical trial success through a purposeful use of data and technology |
|
10:00 – 10:30 |
Networking |
Speakers
 |
Cem Baydar, Ph.D, Senior Principal, Consulting Services, London Current responsibility |
 |
Antonio Iervolino, Associate Principal, IQVIA Current responsibility |
|
Arranged by:
|
In collaboration with:
|
